comparemela.com
Latest Breaking News On - B degrader program - Page 1 : comparemela.com
Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Dose escalation in FHD-286 combination trial in AML continues to progress with clinical data expected in the second half of 2024; potential to be a first-in-class oral broad-based differentiation.
United-states
Massachusetts
Cambridge
Cambridgeshire
United-kingdom
American
Peter-kelleher
Greg-dearborn
Adam-silverstein
Karin-hellsvik
Adrian-gottschalk
B-degrader-program
vimarsana © 2020. All Rights Reserved.